Banque Pictet & Cie SA Has $88.87 Million Stock Position in AbbVie Inc. $ABBV

Banque Pictet & Cie SA lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 16.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 388,924 shares of the company’s stock after purchasing an additional 54,953 shares during the period. AbbVie accounts for 0.5% of Banque Pictet & Cie SA’s holdings, making the stock its 21st biggest position. Banque Pictet & Cie SA’s holdings in AbbVie were worth $88,865,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Linden Thomas Advisory Services LLC raised its holdings in shares of AbbVie by 3.1% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 13,507 shares of the company’s stock valued at $3,086,000 after purchasing an additional 407 shares during the period. Compagnie Lombard Odier SCmA lifted its stake in AbbVie by 5.3% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 322,464 shares of the company’s stock valued at $73,680,000 after purchasing an additional 16,262 shares during the last quarter. Tema Etfs LLC grew its holdings in AbbVie by 7.2% during the fourth quarter. Tema Etfs LLC now owns 51,789 shares of the company’s stock worth $11,833,000 after purchasing an additional 3,475 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in AbbVie by 8.5% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 36,207 shares of the company’s stock worth $8,273,000 after buying an additional 2,833 shares during the last quarter. Finally, Capital Advisors Inc. OK increased its position in AbbVie by 2.3% during the fourth quarter. Capital Advisors Inc. OK now owns 390,570 shares of the company’s stock worth $89,241,000 after buying an additional 8,922 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by company insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Federal tax-law effects: Analysts and reports show U.S. corporate cash taxes fell roughly $65B after recent tax changes, a trend benefiting large pharma cash flow and near-term free cash flow for companies like AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Positive Sentiment: Allergan Aesthetics promotion: AbbVie’s aesthetics unit is running its fourth annual CoolMonth promotion (CoolSculpting offers), which can modestly boost procedure volumes and near-term aesthetics revenue. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
• Neutral Sentiment: Earnings schedule: AbbVie set its Q1 2026 results release and conference call for April 29 (pre-market), a scheduled event that will be the next major catalyst for stock direction. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Mixed intraday moves: Recent headlines show short-term intraday swings (some sessions with gains, others with underperformance versus the market), indicating investor attention is currently fragmented between fundamentals and newsflow. AbbVie Inc. stock rises Tuesday, still underperforms market AbbVie (ABBV) Gains As Market Dips: What You Should Know
• Negative Sentiment: Litigation tied to Cerevel/AbbVie deal: A court ordered Pfizer and Bain to litigate a suit by Cerevel investors over the AbbVie transaction, creating deal-related legal uncertainty and potential distraction or liabilities. That legal cloud can pressure sentiment around transactions and M&A strategy. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Oncology headwinds: Analyst commentary flags likely 2026 revenue pressure in AbbVie’s oncology franchise — pricing pressure on Imbruvica and a near-term dip in legacy oncology sales could offset growth from newer oncology assets. This is a direct revenue-risk item investors care about for 2026 guidance. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?

Analysts Set New Price Targets

A number of analysts have recently issued reports on ABBV shares. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Morgan Stanley increased their price target on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Barclays initiated coverage on AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target for the company. Finally, Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Down 1.3%

Shares of NYSE:ABBV opened at $214.72 on Thursday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The business has a 50 day moving average of $221.98 and a 200-day moving average of $224.58. The stock has a market cap of $379.66 billion, a PE ratio of 90.98, a P/E/G ratio of 0.76 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.